Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Taiwan Reports Record Drug-Development Funds In First Half

This article was originally published in PharmAsia News

Executive Summary

Taiwan reports $86.6 million worth of investments in development of new drugs by its drug makers during the first half of this year, 18 times more than the same period a year ago. The Industry and Technology Intelligence Service said the pharmaceutical portion of the biotechnology industry also invested heavily, registering an investment level of $169.6, nearly half the investments in the overall biotech industry. The ITIS also reported strong growth in exports of biotech products, including biomedical materials and antibodies. (Click here for more

You may also be interested in...

Polaris Taiwan Subsidiary TDW To Begin Phase III Trials Of Liver Cancer Drug

HONG KONG - Phase III clinical trials are slated to start next year on anti-cancer drug ADI-PEG 20 by U.S.-based Polaris Group's Taiwan subsidiary TDW Pharmaceuticals following successful Phase II trials that included recovery by a cancer patient deemed to have six months to live several years ago

IQVIA: US Out-Of-Pocket Drug Costs Stable, But Overall Spending Is Higher

New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.

Teladoc Health Acquires Livongo In $18.5Bn Deal, Creating Virtual Care Giant

The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.   




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts